Metraipolis › archive › dc_7d53b4b77db6
Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality — Europe PMC PPR:PPR308685
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR308685
- DOI
- 10.1101/2021.04.07.438849
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-05T01:39:45.251Z
- SHA-256 of the archived text
81d1355641f56aa638e2a00858fe5d165d55dd186d69c5f4419688dc434cf0c4- Stable URL of this page
https://metraipolis.com/documento/dc_7d53b4b77db6
How to cite
Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality — Europe PMC PPR:PPR308685 — Europe PMC, https://europepmc.org/article/PPR/PPR308685 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7d53b4b77db6 (Metraipolis archive dc_7d53b4b77db6, sha256 81d1355641f56aa638e2a00858fe5d165d55dd186d69c5f4419688dc434cf0c4)
BibTeX
@misc{dc7d53b4b77db6,
title = {Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality — Europe PMC PPR:PPR308685},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR308685},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7d53b4b77db6; sha256 81d1355641f56aa638e2a00858fe5d165d55dd186d69c5f4419688dc434cf0c4},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR308685. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants has sparked concern over the continued effectiveness of existing therapeutic antibodies and vaccines. Hence, together with increased genomic surveillance, methods to rapidly develop and assess effective interventions are critically needed. Here we report the discovery of SARS-CoV-2 neutralizing antibodies isolated from COVID-19 patients using a high-throughput platform. Antibodies were identified from unpaired donor B-cell and serum repertoires using yeast surface display, proteomics, and public light chain screening. Cryo-EM and functional characterization of the antibodies identified N3-1, an antibody that binds avidly (K d,app = 68 pM) to the receptor binding domain (RBD) of the spike protein and robustly neutralizes the virus in vitro . This antibody likely binds all three RBDs of the trimeric spike protein with a single IgG. Importantly, N3-1 equivalently binds spike proteins from emerging SARS-CoV-2 variants of concern, neutralizes UK variant B.1.1.7, and binds SARS-CoV spike with nanomolar affinity. Taken together, the strategies described herein will prove broadly applicable in interrogating adaptive immunity and developing rapid response biological countermeasures to emerging pathogens. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: bioRxiv, 2021 (prima pubblicazione 2021-04-08). Identificativi: DOI 10.1101/2021.04.07.438849. Pagina: https://europepmc.org/article/PPR/PPR308685 — https://doi.org/10.1101/2021.04.07.438849. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-05T01:36:01.693Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.